Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 5, 2000, Pages 597-602

  Fass, R ^a,b   Sampliner, R E ^a   Malagon, I B ^a   Hayden, C W ^a   Camargo, L ^a   Wendel, C S ^a   Garewal, H S ^a  

^a D of G and H O and H S R C   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; FEMALE; HUMAN; MALE; PH MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; DRUG RESISTANCE; ESOPHAGUS; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS;

EID: 0034092949     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00749.x     Document Type: Article

References (38)

1. 1 Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362-71.
2. 2 Pera M, Cameron AJ, Trastek VJ, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3.
3. 3 Devesa SS, Blot WJ. Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
4. 4 Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett's esophagus by laser ablation in an acid environment. Dig Dis Sci 1993; 38: 365-8.
5. 5 Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophagus epithelium. Gastroenterology 1993; 104: 1686-91.
6. 6 Jones R, Barnham CP, Hardwick R, Shepherd N, et al. Regression of columnar-lined esophagus following KTP laser ablation with acid suppression. Gastroenterology 1996; 110: A537(Abstract).
7. 7 Laukka MA, Wang KK. Initial results using low dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 1994; 42: 59-63.
8. 8 Wang KK, Geller A, Gutta K, Laukka M, et al. Photodynamic therapy in the treatment of Barrett's esophagus. Gastroenterology 1996; 110: A290(Abstract).
9. 9 Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 1993; 39: 73-6.
10. 10 Overholt BF, Panhehpour M. Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42: 64-70.
11. 11 Overholt BF, Pannehpour M. Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996; 91: 1719-23.
12. 12 Barr H, Shepherd NA, Roberts DJH. Tan WC, et al. Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-5.
13. 13 Sampliner RE, Fennerty MB, Garewal US. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44: 523-5.
14. 14 Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ, et al. P9 bicap cautery converts Barrett's epithelium to squamous mucosa. Am J Gastroenterol 1995; 90: 1554(3).
15. 15 Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus. Dig Dis Sci 1997; 42: 1853-8.
16. 16 Mulholland MW, Reid BJ, Levine DA, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989; 34: 1329-35.
17. 17 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-61.
18. 18 Collen MJ, Johnson DA. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1992; 37: 570-6.
19. 19 Hirschowitz BI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996; 41: 1384-91.
20. 20 Brandt L, Kaubar D. Laser-induced transient regression of Barrett's epithelium. Gastrointest Endosc 1992; 38: 619-22.
21. 21 Brandt L, Blansky A, Kauvar D. Repeat laser therapy of recurrent Barrett's esophagus: success with anacidity. Gastrointest Endosc 1994; 3: 267.
22. 22 Byrne J, Armstrong G, Attwood S. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-5.
23. 23 Jackson F, Husson M, Wright S, Lipschutz W, DuFrayne F, Aronchick C. Eradication of Barrett's epithelium with multipolar electrocoagulation. Gastrointest Endosc 1997; 45: AB71-187.
24. 24 Kovacs B, Chen Y, Lewis T, DeGuzman L, Thompson K. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999; 9: 547-53.
25. 25 VanLaethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-51.
26. 26 Sampliner RE. Ablative therapies for the columnar lined esophagus. Gastroenterol Clinics N Am 1997; 26: 685-93.
27. 27 Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation used in combination with high dose omeprazole. Gastroenterology 1999; 116: G1339.
28. 28 Sampliner RE. Practice parameters committee of the ACG. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-32.
29. 29 Weiner GJ, Morgan TM. Ambulatory 24-hour esophageal pH monitoring, reproducibility and variability of pH parameters. Dig Dis Sci 1988; 33: 1127-33.
30. 30 Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
31. 32 Just R, Gideon RM, Castell DO. Omeprazole resistance in patients with gastroesophageal reflux. Gastroenterology 1994: 106: A101 (Abstract).
32. 33 Gupta PK. Flockhart N, Soukhova N, et al. Omeprazole metabolism in patients with refractory gastroesophageal reflux (GER). Gastroenterology 1994; 106: A84(Abstract).
33. 34 Leite LP, Johnston BT, Just RJ. Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
34. 35 Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91.
35. 36 Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
36. 37 Khoury RM, Katz PO, Hammond R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13: 675-8.
37. 38 Peters FTM, Kuipers EJ, Ganesh S, et al. The influence of H. pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999; 13: 921-6.
38. 39 Loughney T, Maydonovitch CL, Wong RKH. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol 1998; 93: 916-9.